There is also a greenshoe option of 810,000 shares.
The gene therapy biopharmaceutical company expects to raise net proceeds of $81.9M in the offering, which is due to close on February 10.
Seeking Alpha author Don Dion believes that while "there's no guarantee" that uniQure's main product, Glybera, will catch on, the firm "appears to have long-term potential for success in the gene therapy field."
"Glybera is used to treat a subset of patients with lipoprotein lipase deficiency (LPLD), a dangerous metabolic disease," Dion writes. (PR)